Both in vitro and in vivo studies have shown that increased P2rx7 activity induces proliferation in GLC, LKM and pancreatic cancer (PCC), and its blockade reduces tumor burden in several cancer types and experimental models [77,78,79,80,81,82]. Here, P2RX7 is linked to pancreatic neoplasm.